Back

Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead

European Heart Journal

5 May 2016
Organised by: Logo
Read full article
ESC Journals

Contributors

Caroline K. Kramer
Caroline K. Kramer

Author

Bernard Zinman
Bernard Zinman

Author

You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Session
The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital
17 May 2025
thumbnail
Congress Presentation
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes
27 August 2023
thumbnail
Congress Presentation
A real world experience: Sodium-glucose co-transporter-2 (SGLT2) inhibitors in cancer therapy related cardiac dysfunction (CTRCD)
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources